CELC

Celcuity Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$84.10

+$0.10+0.12%

Delayed · 2026-09-22T20:00:00.000Z · marketstack

5 of 9 open-market sales on file ran under a pre-arranged trading plan ($9.01M), 4 did not. Who, and when

Aug 24, 2026$84.10

−$6.69−7.37%over 1M

Session

Day range48% of range

$82.80$85.50

Fundamentals

Visualize fundamentals and more

Market cap: 4.61B
P/E ratio: -

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2025.

FDA approval
Data privacy
Reimbursement
Litigation
Cybersecurity
AI and its regulation
Key people
Patent expiry

And 12 more.

FDA approval
To date, we have not yet completed any registrational clinical trials or the development of our initial drug candidate, gedatolisib. Our future success and ability to generate revenue, which we do not expect until 2026 or later, if ever, is dependent on our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

23 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 22, 2026 · the last close

Celcuity Inc. investor relations

What CELC has filed with the SEC. This is not Celcuity Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Celcuity Inc.

Also filed under Biotechnology, ranked by how closely they sit beside CELC.

MRNAModerna, Inc.compare with CELC
ROIVRoivant Sciences Ltd.compare with CELC
VRTXVertex Pharmaceuticals Inc. / MA

What an account lets you do with Celcuity Inc.

Be told the moment a CELC insider trades
Put Celcuity Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Celcuity Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Celcuity Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2025.

FDA approval
Data privacy
Reimbursement
Litigation
Cybersecurity
AI and its regulation
Key people
Patent expiry

And 12 more.

FDA approval
To date, we have not yet completed any registrational clinical trials or the development of our initial drug candidate, gedatolisib. Our future success and ability to generate revenue, which we do not expect until 2026 or later, if ever, is dependent on our …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Session

Fundamentals

What it says it is exposed to

Recent activity

Discussion

Celcuity Inc. investor relations

Companies like Celcuity Inc.

Ask about Celcuity Inc.

What an account lets you do with Celcuity Inc.

Recent activity

What it says it is exposed to